Taylor Wessing advised Essential Pharma on its acquisition of European rights to Colobreathe. International specialty pharmaceutical company, Essential Pharma, has acquired the European rights to Colobreathe...
Essential Pharma’s Acquisition of European Rights to Colobreathe
AlveoGene’s Spinout and Seed Investment
Taylor Wessing advised AlveoGene on its complex spinout and launch investment. AlveoGene, a newly established UK gene therapy company, has successfully completed a complex spinout from...
ENOUGH’s €40 Million Financing Round From World Fund and CPT Capital
Taylor Wessing advised World Fund and Ashurst advises CPT Capital. World Fund, a prominent climate venture capital fund, recently invested €40 million in ENOUGH, a food-tech...
Apollo Therapeutics’ $226.5m Series C Financing
Taylor Wessing advised Apollo Therapeutics on its series C funding round. Apollo Therapeutics Limited, a biopharmaceutical company headquartered in Cambridge, has successfully raised $226.5 million in...
Carlyle and PAI Partners’ Acquisition of Theramex
Linklaters and Allen & Overy advised global investment firms Carlyle and PAI Partners, while Latham & Watkins acted for CVC Capital Partners and Theramex. Taylor Wessing...
Best Buy’s Acquisition of Current Health
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised Current Health on the deal. Best Buy announced it had signed an agreement to acquire Current Health,...
WuXi AppTec’s Acquisition of OXGENE
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised WuXi AppTec on the deal. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in...
Rutland Partners’ Investment in JSM Group
Philip Lee advised JSM on the investment. Taylor Wessing advised Rutland Partners. Private equity investor, Rutland Partners, has completed its investment in JSM Group, a UK-based...